Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS906 in C3G and ICGN
NCT06209736Phase 2Terminated
- Sponsor
- Omeros Corporation
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of zaltenibart in Complement 3 glomerulopathy (C3G), idiopathic immune complex-mediated glomerulonephritis (ICGN), sponsored by Omeros Corporation. Started Mar 2024; status: terminated.
02
Drugs
zaltenibart
03
Conditions
Complement 3 glomerulopathy (C3G)idiopathic immune complex-mediated glomerulonephritis (ICGN)
Beyond the preview
Go deeper on NCT06209736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209736.